VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.14% | -49.81% | -40.64% | -43.21% | -121.87% |
| Total Depreciation and Amortization | 17.39% | 17.83% | 11.92% | 12.93% | 12.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.56% | -2.26% | -30.41% | 58.14% | 92.90% |
| Change in Net Operating Assets | -95.28% | 378.12% | -230.11% | 38.21% | 180.17% |
| Cash from Operations | -71.51% | -26.39% | -73.39% | -44.05% | -116.56% |
| Capital Expenditure | -- | 1.64% | -54.76% | -203.45% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 130.81% | 99.56% | 86.67% | -- | -- |
| Cash from Investing | 124.64% | 98.79% | 85.59% | 1,917.24% | -1,218.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 104.10% | -- | 534.09% | -- | -98.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 80.36% | -- | 1,590.91% | 613.42% | -98.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.74% | 173.91% | -11.68% | -2.57% | -110.71% |